Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12ETN | ISIN: CA98420N1050 | Ticker-Symbol: XP0
Tradegate
27.03.25
16:49 Uhr
32,200 Euro
+0,600
+1,90 %
1-Jahres-Chart
XENON PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
XENON PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
30,80031,20022:04
30,60031,60022:00

Aktuelle News zur XENON PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.03.Xenon Pharmaceuticals Inc. - 8-K, Current Report4
12.03.Xenon Pharmaceuticals Inc.: Xenon to Present at Stifel 2025 Virtual CNS Forum 1
05.03.Xenon Pharmaceuticals Inc. - 8-K, Current Report1
XENON PHARMACEUTICALS Aktie jetzt für 0€ handeln
27.02.Xenon Pharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans-
27.02.Xenon Pharmaceuticals Inc.: Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update164- Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch - First of three planned Phase 3 azetukalner MDD studies...
► Artikel lesen
27.02.Xenon Pharmaceuticals Inc. - 10-K, Annual Report-
20.02.Xenon Pharmaceuticals Inc.: Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 20251
24.01.FY2029 Earnings Estimate for XENE Issued By Wedbush2
17.01.Xenon Pharmaceuticals Inc. - 8-K, Current Report5
13.01.Xenon Pharmaceuticals Inc.: Xenon Outlines Key Corporate Milestone Opportunities for 2025121- Topline data from the first Phase 3 FOS study anticipated in H2 2025 representing major milestone in support of NDA filing and potential launch of azetukalner - First of three planned Phase 3 MDD...
► Artikel lesen
06.12.24Xenon Pharmaceuticals Inc.: Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024206- OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner...
► Artikel lesen
25.11.24Xenon Pharmaceuticals Inc.: Xenon to Showcase New Long-Term Azetukalner Data at AES 20241
12.11.24Xenon Pharma GAAP EPS of -$0.81 in-line2
12.11.24Xenon Pharmaceuticals Inc.: Xenon Reports Q3 2024 Financial Results and Business Update247- Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025 - Long-term azetukalner results from X-TOLE open-label extension study in FOS to be presented at AES - Phase...
► Artikel lesen
12.11.24Xenon Pharmaceuticals Inc. - 10-Q, Quarterly Report-
11.11.24Xenon Pharma Q3 2024 Earnings Preview1
11.11.24Earnings Preview: Xenon Pharmaceuticals1
05.11.24Xenon Pharmaceuticals Inc.: Xenon to Report Q3 2024 Financial Results on November 12, 20242
10.10.24Raymond James sets steady target on Xenon Pharmaceuticals3
10.10.24Raymond James setzt stabiles Kursziel für Xenon Pharmaceuticals11
Seite:  Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1